Leaning on its in-house life sciences expertise GV has backed another biotech startup in the UK, co-leading a £20 million ($27.1M) Series A in Oxford University spinout Vaccitech, which is developing a universal flu vaccine. Sequoia China, another new investor, is also co-leading the round, along with existing backer Oxford Sciences Innovation (OSI) — which operates a …
Continue reading “GV co-leads $27.1M Series A in Oxford Uni life sciences spinout Vaccitech”